1269232-96-3 Usage
General Description
Benzenamine, 5-chloro-2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- is a specialized chemical, commonly used in the field of synthetic organic chemistry. It is also known by other names such as Boronic acid, B-(5-chloro-2-fluoro-3-aminophenyl)-, tetramethyl ester, and its CAS number is 1244737-61-8. Its unique molecular structure with boron, chlorine, and fluorine components allows it to be utilized as a reagent in advanced research and development processes, particularly for the creation of bioactive molecules, pharmaceutical intermediates, or other complex organic molecules. Due to its specific applications and potential hazard, handling of this substance should be executed by professionals or under professional supervision.
Check Digit Verification of cas no
The CAS Registry Mumber 1269232-96-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,6,9,2,3 and 2 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1269232-96:
(9*1)+(8*2)+(7*6)+(6*9)+(5*2)+(4*3)+(3*2)+(2*9)+(1*6)=173
173 % 10 = 3
So 1269232-96-3 is a valid CAS Registry Number.
1269232-96-3Relevant articles and documents
COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS
-
Paragraph 0947; 0948, (2021/01/20)
Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.
COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
-
Page/Page column 53, (2011/04/14)
The invention provides a novel class of compounds of formula 1, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
